Page last updated: 2024-09-03

gefitinib and Atrophy

gefitinib has been researched along with Atrophy in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (50.00)29.6817
2010's1 (50.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Demehri, FR; Dempsey, PJ; Feng, Y; Freeman, JJ; Teitelbaum, DH1
Hare, KJ; Hartmann, B; Holst, JJ; Kissow, H; Poulsen, SS1

Other Studies

2 other study(ies) available for gefitinib and Atrophy

ArticleYear
TPN-associated intestinal epithelial cell atrophy is modulated by TLR4/EGF signaling pathways.
    FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2015, Volume: 29, Issue:7

    Topics: Animals; Apoptosis; Atrophy; Cell Proliferation; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Interferon-gamma; Intestinal Mucosa; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Parenteral Nutrition, Total; Quinazolines; RNA, Messenger; Signal Transduction; Toll-Like Receptor 4; Tumor Necrosis Factor-alpha

2015
The intestinotrophic peptide, glp-2, counteracts intestinal atrophy in mice induced by the epidermal growth factor receptor inhibitor, gefitinib.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2007, Sep-01, Volume: 13, Issue:17

    Topics: Animals; Antineoplastic Agents; Atrophy; Body Weight; ErbB Receptors; Female; Gefitinib; Glucagon-Like Peptide 2; Intestines; Mice; Mice, Inbred C57BL; Organ Size; Quinazolines

2007